Leadership Overview
Sarepta Therapeutics has 7 executives leading key functions including strategy, operations, research, people, and medical affairs.
Driven by a commitment to innovation, Sarepta Therapeutics is dedicated to discovering, developing, and commercializing precision genetic medicines for rare diseases, aiming to transform patient lives globally.
Driven by a commitment to innovation, Sarepta Therapeutics is dedicated to discovering, developing, and commercializing precision genetic medicines for rare diseases, aiming to transform patient lives globally.
Leadership Roles at Sarepta Therapeutics
Ian Estepan - President & Chief Operating Officer
Ian Estepan, the President & Chief Operating Officer at Sarepta Therapeutics, orchestrates the company's global operational functions and drives execution across all business units. Estepan oversees manufacturing, supply chain, commercial operations, and infrastructure development, ensuring seamless delivery of Sarepta's precision genetic medicines. This leadership position involves optimizing operational efficiency and scalability to meet the growing demand for novel treatments for rare neuromuscular and central nervous system disorders. By fostering a culture of operational excellence, Ian Estepan directly supports the company's commitment to patients worldwide. The strategic imperative includes managing complex global logistics and ensuring robust production capabilities for FDA-approved therapies and pipeline assets.
Louise Rodino-Klapac - President, Research Development & Technical Operations
Louise Rodino-Klapac, the President, Research Development & Technical Operations at Sarepta Therapeutics, leads the company's scientific innovation and manufacturing capabilities. Rodino-Klapac directs the discovery and development of novel genetic medicines, overseeing the entire research pipeline from early-stage exploration to late-stage clinical development. Simultaneously, this executive drives technical operations, ensuring the robust and scalable manufacturing of Sarepta's approved therapies and investigational products. This dual focus is critical for translating cutting-edge science into tangible treatments for rare diseases, particularly Duchenne muscular dystrophy. Louise Rodino-Klapac's leadership ensures the integration of scientific advancement with operational readiness, supporting Sarepta's global mission to impact patient lives.
William Tilton - Senior VP, Corporate Strategy & Chief of Staff
William Tilton, the Senior VP, Corporate Strategy & Chief of Staff at Sarepta Therapeutics, directs strategic initiatives and operational alignment across the organization. Tilton oversees the development and execution of corporate strategies, ensuring coherence between long-term goals and day-to-day operations. This leadership role involves close collaboration with executive peers to refine market positioning and drive sustainable growth. By integrating strategic planning with functional execution, William Tilton supports the company's mission to deliver transformative genetic medicines. The scope of this position includes fostering cross-departmental synergy to accelerate pipeline advancement and commercial success, directly impacting Sarepta's global reach in rare disease therapeutics.
Zohal Ghiaszada - Senior Director, Chief of Staff To Chief Medical and Regulatory Officer
Zohal Ghiaszada, the Senior Director, Chief of Staff To Chief Medical and Regulatory Officer at Sarepta Therapeutics, provides critical operational and strategic support to the Chief Medical and Regulatory Officer. Ghiaszada manages key projects and initiatives, ensuring efficient execution of medical and regulatory strategies. This role involves facilitating communication and coordination between the medical affairs, regulatory affairs, and other key departments. By streamlining processes and enhancing decision-making, Zohal Ghiaszada contributes to the timely advancement of Sarepta's therapeutic programs. The focus remains on supporting the development and approval of precision genetic medicines for rare diseases, aligning operational efforts with global compliance standards.
Kirsten M. - Head of Medical Operations & Program Management, Global Medical Affairs Chief of Staff
Kirsten M., the Head of Medical Operations & Program Management, Global Medical Affairs Chief of Staff at Sarepta Therapeutics, directs the operational framework for global medical affairs and manages critical program management functions. M. ensures the effective execution of medical strategies, overseeing program timelines, resource allocation, and cross-functional coordination. This role is pivotal in translating scientific insights into actionable medical plans and supporting the commercialization of Sarepta's genetic therapies. By enhancing operational efficiency within medical affairs, Kirsten M. contributes to the company's mission of bringing life-changing treatments to patients with rare diseases. The focus includes optimizing program delivery and ensuring alignment with regulatory and scientific standards across global markets.
Kirsten Meisterling - Senior Director, Chief of Staff To Senior Vice President, Medical Affairs
Kirsten Meisterling, the Senior Director, Chief of Staff To Senior Vice President, Medical Affairs at Sarepta Therapeutics, provides essential strategic and operational support to the Senior Vice President of Medical Affairs. Meisterling facilitates the execution of medical affairs strategies, manages key projects, and ensures effective communication across internal teams and external stakeholders. This position is critical for driving the operational aspects of medical affairs initiatives, supporting the development and dissemination of scientific information related to Sarepta's precision genetic medicines. By optimizing workflows and enhancing strategic alignment, Kirsten Meisterling contributes to the company's efforts to address unmet needs in rare diseases. The role emphasizes efficient project management and support for the advancement of medical science.
Alison Nasisi - Executive Vice President & Chief People Officer
Alison Nasisi, the Executive Vice President & Chief People Officer at Sarepta Therapeutics, directs all human capital strategies and organizational development initiatives. Nasisi oversees talent acquisition, employee engagement, compensation and benefits, and diversity and inclusion programs, fostering a high-performance culture aligned with Sarepta's mission. This leadership role is essential for attracting, retaining, and developing the specialized talent required for advancing precision genetic medicines. By championing people-centric policies and programs, Alison Nasisi ensures that Sarepta's workforce is equipped to drive innovation and execute complex scientific and commercial objectives. The focus remains on building a supportive and dynamic environment that empowers employees to contribute to the company's success in rare disease therapeutics.
Explore Leadership Teams in Manufacturing
PCI Pharma Services is an integrated full service provider to companies in the global healthcare industry. They offer services including analytical services, formulation development, clinical trial supply, commercial manufacturing and packaging, QP services, supply chain management, storage, and distribution. They are headquartered in Philadelphia, Pennsylvania with locations in the United States and Europe.
Company Leadership HL
ED
LR
BK
Founded in 1967, Douglas Pharmaceuticals is a manufacturer of pharmaceutical products. The company started out distributing prescription medicines, before manufacturing and later successfully researching and developing its products for export. The company is headquartered in Auckland, New Zealand.
Company Leadership SW
TB
AM
BL
Founded in 2005, Headquartered in Tokyo, Daiichi Sankyo is a global pharmaceutical company that develops and provides innovative new and generic medicines, as well as advanced drug discovery and delivery methods, serving patients in over 30 countries.
Company Leadership KI
KM
CS
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Company Leadership TI
CS
SP
MD
Frequently Asked Questions Regarding Sarepta Therapeutics Top Executives and Leadership Team
Unlock more people and company data
